Zvonimir Majic, PhD, Teva, on behalf of the PDA Pharmaceutical Cold Chain Interest Group, (EU) | Jan 30, 2017
Temperature excursions and delays at airports are major concerns for companies shipping temperature-sensitive pharmaceutical products
by air. In light of this, last fall, the International Air Transport Association (IATA) presented their Center of Excellence for Independent
Validators (CEIV) certification program to the European steering committee of PDA’s Pharmaceutical Cold Chain Interest Group.
IATA represents 265 airlines that account for approximately 83% of total air traffic. The CEIV certification program was developed in
2014 as part of an effort to harmonize the air transport industry’s practices for shipment of pharmaceutical product and accommodate
the pharmaceutical industry’s GDP expectations. This program emphasizes the importance of having defined quality and risk management
systems in place to address requirements coming from global regulators. IATA intends to provide the pharmaceutical manufacturing
industry a harmonized standard for handling and transporting healthcare products worldwide through a network of CEIV-certified
airlines, airports, ground handling agents, trucking companies, and forwarders.
The interest group’s European steering committee welcomes this initiative as a valuable effort in the joint quest of the airline and pharmaceutical
industries to deliver safe healthcare products to patients. This program intends to deliver quality and risk management systems
in the logistics industry designed according to mainstream GDP regulatory documents (MHRA, USP, EMA). Considering the increase
in the complexity of the pharmaceutical supply chain, a network of CEIV-certified suppliers would undoubtedly enhance controls and
visibility throughout the air freight industry.
More information about the program can be found here.